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Although the treatment of acute myeloid leukemia (AML) has improved substantially in the past three decades, more than half of all patients develop disease that is refractory to intensive chemotherapy 1, 2 . Functional genomics approaches offer a means to discover specific molecules mediating the aberrant growth and survival of cancer cells [3] [4] [5] [6] [7] [8] . Thus, using a loss-of-function RNA interference genomic screen, we identified the aberrant expression of hepatocyte growth factor (HGF) as a crucial element in AML pathogenesis. We found HGF expression leading to autocrine activation of its receptor tyrosine kinase, MET, in nearly half of the AML cell lines and clinical samples we studied. Genetic depletion of HGF or MET potently inhibited the growth and survival of HGFexpressing AML cells. However, leukemic cells treated with the specific MET kinase inhibitor crizotinib developed resistance resulting from compensatory upregulation of HGF expression, leading to the restoration of MET signaling. In cases of AML where MET is coactivated with other tyrosine kinases, such as fibroblast growth factor receptor 1 (FGFR1) 9 , concomitant inhibition of FGFR1 and MET blocked this compensatory HGF upregulation, resulting in sustained logarithmic cell killing both in vitro and in xenograft models in vivo. Our results show a widespread dependence of AML cells on autocrine activation of MET, as well as the key role of compensatory upregulation of HGF expression in maintaining leukemogenic signaling by this receptor. We anticipate that these findings will lead to the design of additional strategies to block adaptive cellular responses that drive compensatory ligand expression as an essential component of the targeted inhibition of oncogenic receptors in human cancers.
We used a doxycycline-inducible retroviral RNAi library of 5,087 barcoded shRNAs targeting 1,740 human genes to screen for functional pathway dependence in OCI-AML2 cells derived from a patient with complex-karyotype AML ( Supplementary Fig. 1a ) 10 . Among the 30 genes most substantially required for the proliferation and survival of OCI-AML2 cells but not cells from a variety of nonmyeloid hematologic malignancies was HGF, the ligand of the receptor tyrosine kinase MET (Fig. 1a) 11 . Targeting of HGF and downstream mediators of the MET signaling pathway, such as STAT3 and MAPK1, with two independent shRNAs markedly suppressed the growth of AML cells but not of nonmyeloid hematologic cancer cells ( Supplementary Fig. 1b-d) .
In tests of the functional consequences of HGF expression in AML cell lines, we found that in four of seven AML cell lines, but not normal CD34 + cells, expressed HGF was associated with MET activation (Fig. 1b) . Given that normal CD34 + cells do not express HGF, these data indicate that HGF expression by AML cells is aberrant, whereas expression of MET is lineage appropriate. Knockdown of HGF using two independent specific shRNAs inhibited the growth of OCI-AML2 cells ( Fig. 1c and Supplementary Fig. 2a ). This effect could be rescued with recombinant HGF protein (0.1 nM) or by the transduction of complementary DNA (cDNA) encoding HGF (Fig. 1c) . OCI-AML2 cell growth was also inhibited by the addition of a neutralizing antibody against HGF (100 nM) to the culture medium (Fig. 1c) . We also showed the requirement for HGF and MET signaling in three additional AML cell lines (HEL, SKNO-1 and KG-1) by depleting HGF and MET using specific shRNAs and inhibiting MET kinase signaling using the kinase inhibitor SU11274 (1 µM) ( Supplementary  Figs. 3-5) . Inhibition of HGF and MET signaling led to a significant increase in the apoptosis of HGF-expressing cells (Fig. 1d) without Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia the induction of cell-cycle arrest (Supplementary Fig. 3 ). In addition, treatment with the specific MET kinase inhibitor crizotinib (100 nM) led to decreased colony formation of HGF-expressing primary AML samples (Fig. 1e,f ) . Taken together, our findings indicate that cellautonomous production of HGF causes autocrine activation of MET and is necessary for the proliferation or survival of HGF-expressing AML cells.
To estimate the prevalence of aberrant HGF and MET signaling in patients with AML, we used immunohistochemistry to detect the coexpression of HGF and MET in bone marrow biopsy specimens from 138 adults with a broad spectrum of AML subtypes (Fig. 2a-c and Supplementary Fig. 6a-e) . These proteins were expressed together in 58 (42%) of the patients (Fig. 2c) , often in association with specific genetic abnormalities, including the PML-RARA and AML1-ETO (also known as RUNX1-RUNX1T1) translocations ( Supplementary  Fig. 6f ). Using a capillary isoelectric focusing electrophoresis nanoimmunoassay, which allows for precise quantification of differences in protein expression and phosphorylation, we observed expression of HGF and activation of MET in 5 (38%) of 13 viably frozen bone marrow aspirate specimens (Supplementary Fig. 7 ) and confirmed these results using flow cytometry (Supplementary Fig. 8 ). In the cohort we examined, there was no statistically significant difference in survival between patients with and without aberrant HGF expression (Supplementary Fig. 6g ). An additional analysis of the gene expression profiles of primary blasts from 285 patients with AML using unsupervised clustering also revealed the high expression of HGF in a subset of patients with AML 12 , including patients with the with PML-RARA or AML1-ETO translocations (Supplementary Fig. 9 ).
Because HGF expression is associated with specific biologic subtypes of AML, we hypothesized that it might be induced by chimeric transcription factors that act in trans on the HGF locus to drive AML pathogenesis. Consistent with this concept, we did not detect any copy number changes ( Supplementary Fig. 10a,b) , mutations of the HGF promoter (Supplementary Fig. 10c ) or allelic skewing of single nucleotide polymorphism expression ( Supplementary  Fig. 10d ) in human AML cell lines with aberrant HGF expression. To test this predicted trans-acting mechanism directly, we transduced primary lineage-depleted mouse hematopoietic cells with fusionprotein-encoding retroviruses and monitored them for expression of HGF and activation of MET using nanoimmunoassays. Cells transduced with retroviruses encoding PML-RARA, PLZF-RARA (also known as ZBTB16-RARA) or AML1-ETO expressed HGF ( Fig. 2d and Supplementary Fig. 11 ) and showed phosphorylation of MET ( Fig. 2e and Supplementary Fig. 11 ). The transformed cells were sensitive to MET kinase inhibition in serial replating colony-formation assays ( Fig. 2f and Supplementary Fig. 11 ) and showed downregulation of MET phosphorylation ( Fig. 2g and Supplementary Fig. 11) To assess the potential of HGF and MET signaling as a therapeutic target, we investigated the sensitivity of HGF-and MET-dependent AML cell lines to chemical inhibition of the MET kinase using the specific MET and anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitor crizotinib 13 , which permits targeting of MET in AML because ALK is not expressed by hematopoietic cells or by any of the AML cell lines studied to date (Supplementary Fig. 3b ). The growth of AML cell lines with aberrant HGF expression and MET activation was strongly inhibited by treatment with crizotinib (100 nM), whereas the growth of cell lines lacking HGF expression and MET activation was unaffected by crizotinib treatment ( Fig. 1d and Supplementary  Fig. 4e,f) . However, HGF-expressing cells treated for more than 6 d with crizotinib seemed to regain their normal growth rate ( Fig. 3a and Supplementary Fig. 12a,b) .
Further experiments to determine the origin of the acquired resistance to crizotinib using quantitative nanoimmunoassays showed a profound inhibition of MET activation within 12 h of crizotinib treatment in OCI-AML2 cells (Supplementary Fig. 13a ) that was associated with the induction of apoptosis (Supplementary Fig. 14) . In addition, we observed a 13-fold upregulation of HGF in crizotinib-treated compared to vehicle-treated OCI-AML2 cells (Supplementary Fig. 13b ), which occurred in concert with the recovery of the amount of phosphorylated MET after 10 d of treatment (Supplementary Fig. 13a) , accounting for the restoration of pretreatment cell growth rates (Fig. 3a) . This finding, confirmed in three different AML cell lines ( Supplementary  Fig. 12c ), reflects an increased biallelic expression of HGF mRNA after crizotinib treatment (Supplementary Fig. 15 ). The recovery of MET phosphorylation corresponded with a recovery in the abundance of phosphorylated CRKL, phosphorylated signal transducer and activator of transcription 3 (STAT3) and phosphorylated mitogen-activated protein kinases 3/1 (ERK1/2) ( Supplementary Fig. 13d-f) , which are all associated with marked upregulation of HGF ( Supplementary  Fig. 13b) . Depletion of HGF with a specific shRNA partially mitigated the compensatory upregulation of HGF in response to MET kinase inhibition, but this strategy was only partially successful in inhibiting leukemia growth in vivo because of the intrinsic variability in knockdown efficiency (Supplementary Figs. 16 and 17) . Although the rapid development of crizotinib resistance was somewhat surprising to us, the selective pressure to maintain MET phosphorylation by upregulation of HGF reinforces our original conclusion that specific types of AML require aberrant HGF-mediated activation of MET signaling for sustained growth and survival.
As activation of MET can occur in AMLs that also harbor aberrant activation of other receptor tyrosine kinases, we reasoned that the combined inhibition of the signaling pathways that are coactivated with MET might be required to block the compensatory upregulation of HGF. In this study, we focused on the coactivation of FGFR1 with HGF and MET in KG-1 cells, which bear a FGFR1OP2-FGFR1 chromosomal translocation and are derived from aggressive 8p11 myeloproliferative syndrome/stem cell leukemia 9 . After treating KG-1 cells with various concentrations of crizotinib and PD173074, a specific and potent inhibitor of the FGFR1 tyrosine kinase 14 , we analyzed the effects using an isobologram analysis ( Supplementary  Fig. 18a ). Nearly all dose combinations of PD173074 and crizotinib produced synergistic effects, as indicated by their low combination index values (Supplementary Fig. 18a ). We found that the effect of PD173074 (20 nM) was mediated specifically by inhibition of FGFR1, as depletion of FGFR1 sensitized KG-1 cells to treatment with crizotinib (Supplementary Fig. 19 ).
Combination treatment of KG-1 cells with 100 nM crizotinib and 20 nM PD173074 (corresponding to their individual half-maximal inhibitory concentration (IC 50 ) values) prevented the compensatory upregulation of HGF (Fig. 3b) , leading to sustained inhibition of MET phosphorylation (Fig. 3c) and sustained blockade of downstream signaling pathways (Supplementary Fig. 18b-f ). This strategy also led to potent induction of apoptosis and logarithmic cell killing that was sustained for 14 d of treatment (Fig. 3) . We confirmed the ontarget effect of PD173074 by specifically depleting cells of FGFR1 by Fig. 19c ). Thus, FGFR1 activity is required for the compensatory upregulation of HGF in response to MET inhibition. We then evaluated the simultaneous inhibition of MET and a blockade of compensatory HGF expression in KG-1 cells modified to express luciferase for bioluminescence imaging, which we engrafted into immunocompromised mice by tail vein injection. We treated the leukemic mice with vehicle control, crizotinib (50 mg per kg body weight) alone, PD173074 (25 mg per kg body weight) alone or a combination of the two agents by daily oral gavage 10 d after transplantation of the leukemia cells. Mice treated with the single drugs or the vehicle control continued to show exponentially growing leukemia, whereas mice treated with both crizotinib and PD173074 had significant regression in disease after 10 d of therapy, as measured by bioluminescence (Fig. 4a,b) . We confirmed these results by flow cytometry, finding a near-complete ablation of CD45 + human cells in the peripheral blood and bone marrow of mice treated with the combination of crizotinib and PD173074 but not in those treated with either drug alone or with the vehicle control (Fig. 4c,d ). Although PD173074 alone had more potent effects on cell growth than crizotinib alone, they were only modest at best, indicating that the striking therapeutic synergy of this combination stems primarily from the PD173074-induced blockade of compensatory HGF upregulation in response to crizotinib treatment (Fig. 4e,f ) . We have identified aberrant HGF and MET signaling as a requisite pathway in the growth and survival of AML cells in nearly half of the primary clinical samples from a large group. In addition to HGF, our genome-wide shRNA screen identified a number of other genes as crucial factors in the biochemical processes that drive AML pathogenesis, which, with proper validation, could offer a functional taxonomy of AML cells, provide powerful insights into the pathophysiology of the disease and, ultimately, offer targets for improved therapy.
How does aberrant production of HGF contribute to the pathobiology of AML? We show here that dysregulated expression of this secreted growth factor, caused in part by the activity of distinct AMLassociated transcription factors, leads to autocrine activation of the MET receptor and, in turn, to autocrine receptor tyrosine kinase signaling, as originally postulated on the basis of first-principle considerations 15 . Instead of direct mutational activation 16 , we found that MET is activated in AML as a result of aberrant autocrine signaling by HGF, which seems to be dynamically controlled, as indicated by the upregulation of HGF in response to chronic MET kinase inhibition. Because constitutive activation of growth factor signaling pathways can have maladaptive cellular effects, such as cell-cycle arrest and senescence 17 , these findings suggest that HGF deregulation and autocrine signaling provide a mechanism by which MET activity can be modulated to levels that optimize the fitness of AML cells, a property that may not be achieved by mutational activation of MET. In addition, HGF seems to be one of the most differentially expressed genes in the leukemia-initiating cells of AML as compared to normal hematopoietic stem cells 18 , suggesting that aberrant HGF and MET signaling may contribute to the growth and survival of AML stem cells, thus strengthening the rationale for targeting this pathway.
Our study also raises the possibility that ligand-induced receptor activation may provide a general mechanism through which cancer cells can develop resistance to the therapeutic inhibition of receptor tyrosine kinase signaling. Autocrine signaling is widely prevalent in human cancers, affecting the epidermal GFR (EGFR), insulin-like GFR (IGFR), platelet-derived GFR (PDGFR), fibroblast GFR (FGFR), neurotrophic tyrosine kinase (TRK), EPH and TIE receptor families, many of which are currently being explored as therapeutic targets 19 . Indeed, ligand-dependent activation of receptor tyrosine kinases has been observed with other leukemogenic receptor tyrosine kinases, most notably the KIT oncogene and fms-related tyrosine kinase 3 (FLT3) 20 . Treatment with FLT3 kinase inhibitors leads to upregulation of the FLT3 ligand 21 , which may be responsible, at least in part, for the diminished clinical efficacy of FLT3 inhibitors in patients with AML 22 . Autocrine or paracrine ligand-induced receptor activation will probably mitigate the effects of the targeted kinase inhibitors of these receptors in a manner that is analogous to the mechanisms by which HGF antagonizes inhibition of the MET kinase by crizotinib. Adaptive increases in ligand expression provide a means for cancer cell populations to re-establish the signal transduction pathways that existed before the onset of inhibitor treatment.
Clinical strategies will need to be developed to effectively overcome ligand-mediated resistance to targeted therapies. In the case of 8p11 stem cell leukemia involving FGFR1 translocations, FGFR1 activity is required for the compensatory upregulation of HGF in response to MET inhibition. Combined inhibition of these coactivated pathways is highly synergistic as a result of the blockade of compensatory HGF upregulation, which leads to the sustained logarithmic cell killing that is required for clinically effective therapy.
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and 55H2 from Cell Signaling Technology). Phosphorylation-specific isoforms were identified by blotting with phosphorylation-specific antibodies (D26 and 55H2 from Cell Signaling Technology for phosphorylated MET (pMET) and pFGFR1, respectively) or by using published nanoimmunoassays (Cell Biosciences). Proteins were detected by time-resolved chemiluminescence (60, 120, 240 and 960 millisecond exposures) using appropriate horseradish peroxidase-conjugated secondary antibodies and probed at a 1:100 dilution for 60 min. Time-resolved chemiluminescence profiles were used to identify the linear detection range, and those profiles in the linear detection range were fit to calculate peak areas and carry out baseline subtraction, as implemented in Compass 1.4.3 (Cell Biosciences).
Immunohistochemistry. Immunohistochemistry was performed using 4-µm formalin-fixed, paraffin-embedded tissue sections, which were soaked in xylene, passed through graded alcohols and washed in distilled water. For HGF and MET, slides were pretreated in a steam pressure cooker (decloaking chamber, BioCare Medical) with 1 mM EDTA, pH 8.0, and 10 mM citrate, pH 6.0, respectively. For HGF, antibody to human HGF (AF-294NA, R&D Systems) was applied in Dako diluent at 1:250 for 1 h. For MET, antibody to human MET (MET4, G.V.W.) was applied in Dako diluent at 1:500 for 1 h. Slides were then washed, and the appropriate secondary antibodies were applied at 1:1,500 in Dako diluent for 1 h. Immunohistochemical staining was detected using the EnVision+ kit, as per the manufacturer's instructions (Dako). Staining was quantified using the Aperio Digital Pathology Environment (Aperio). Specimens were classified as coexpressing HGF and MET if AML blasts identified by their morphology expressed 1+ (low), 2+ (moderate) or 3+ (high) of both proteins.
Primary specimens. AML diagnostic specimens were collected with informed consent and the approval of the Institutional Review Boards of the University of Manchester or the Dana-Farber Cancer Institute.
Mouse xenografts.
Mouse studies were conducted with the approval of the Institutional Animal Care and Use Committee (Dana-Farber Cancer Institute and Northwestern University). NOD-SCID IL-2Rγ-null mice at 6-8 weeks of age (Jackson Laboratory) were transplanted with 1 million cells modified to express firefly luciferase by tail vein injection. Leukemia burden was monitored using whole-body bioluminescence, as previously described 26 . Mice were imaged every 5-7 d after injection, and mice with established leukemia, as assessed by exponentially increasing bioluminescence, were divided into treatment cohorts. Crizotinib and PD173074 were dissolved in aqueous 50 mM sodium acetate, pH 4 (vehicle), and were administered in combination, with at least 4 h between the administration of the individual drugs. Disease burden after treatment was assessed using serial imaging, flow cytometry and nanoimmunoassays. Peripheral blood and femoral bone marrow cells were harvested using standard methods and depleted of red cells using ammonium chloride lysis before analysis. For nanoimmunoassays, human AML cells were further purified using human-specific CD45 MicroBeads (MACS Miltenyi Biotec).
Flow cytometry. CD34-purified AML cells were fixed and permeabilized with 70% ethanol and stained with either IgG1 κ isotype control (1:10,000; eBioscience) or specific antibodies (1:10,000; MET: L41G3 and 3D7 from Cell Signaling Technology; HGF: 1:2,000; H-145 from Santa Cruz). Cells stained with primary antibodies were co-stained with rabbit IgG-specific Alexa 488 and mouse IgG-specific Alexa 647 fluorescently conjugated secondary antibodies.
Collection of patient samples. For the analysis of HGF and MET expression in bone marrow biopsies of patients with AML, patients had presented to the Department of Haematology at the Manchester Royal Infirmary, UK between 1994 and 2005. The samples used comprised residual diagnostic material and were collected with informed consent and the approval of the Institutional Review Board of the University of Manchester (LREC 01/298). Freshly obtained trephine biopsies were immediately fixed in 10% (v/v) neutral buffered formalin (Genta Medical) for 24 h and decalcified in 20% (w/v) EDTA, pH 7.4, for 48 h. Samples were dehydrated and embedded in paraffin wax using a Leica ASP300 smart tissue processor (Leica Microsystems). For the analysis of MET signaling, bone marrow aspirates were collected from patients at the Dana-Farber Cancer Institute and viably frozen in 10% DMSO after obtaining informed consent (DFCI 01-206). For nanoimmunoassays and flow cytometry analyses, cells were thawed, depleted of red cells using ammonium chloride lysis and purified using human CD34 MicroBeads (MACS Miltenyi Biotec).
Data and statistical analyses. The doubling time was calculated using the formula t 1/2 = i ln 2/ln (c 2 /c 1 ), where c 2 and c 1 are the number of cells at the end and beginning of the time interval i, respectively. IC 50 was calculated using the formula y = a + (b − a)/(1 + x/IC 50 ) n , where y is cell viability, a and b are the high and low baselines, respectively, x is drug concentration and n is the Hill coefficient. The combined drug effects were analyzed using the median effect method as implemented in CalcuSyn 2.0 (Biosoft). Time-to-event distributions were calculated using the Kaplan-Meier method. Statistical significance was assessed using Student's t test with two-tailed comparisons for biological measurements and using the log rank test for the comparison of survival distributions. Calculations were performed using Origin 8 (Microcal).
Additional methods. Detailed methodology is described in the Supplementary Methods. 
